GlobeNewswire Inc | Mar 2, 2021 08:30AM EST

March 02, 2021

WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced thatFabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being heldvirtually March 9-10, 2021.

The presentation will be available on-demand beginning onTuesday, March 9, 2021, in the Investors section on the Companys website atwww.bellerophon.com.

About BellerophonBellerophon Therapeuticsis a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulseprogram, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com.

Contacts

At W2O Group: At LifeSci Advisors:Julie Normart Brian Ritchie(559) 974-3245 (212) 915-2578jnormart@w2ogroup.com britchie@lifesciadvisors.com